Purpose. To compare walking characteristics of individuals with Parkinson's disease (PD) using a new walking aid, the WalkAbout, with usual walking. Method. Fifteen subjects with PD were recruited. Subjects walked in their usual fashion and then walked again in the WalkAbout. Gait parameters, 5-min walk, and oxygen consumption were recorded. Results. Stride lengths were shorter when using the WalkAbout. On an average, the distance walked in 5 min and the oxygen uptake was not different when walking with the WalkAbout compared with the usual walk. Eight subjects (responders) walked further with the WalkAbout compared to their usual walk (164.90 + 55.72 m vs. 140.82 + 55.94 m). Seven subjects (non-responders) walked a shorter distance while using the WalkAbout compared to their usual walk (241.79 + 73.06 m vs. 281.24 + 82.83 m). Compared to non-responders, responders were older, had more severe disability, and were more likely to use an assistive device for walking. Responders walked more slowly, had a shorter stride length, and walked shorter distances in 5 min than non-responders. Conclusion. The WalkAbout may help persons with PD who have more severe disability to walk farther. These data could be beneficial in selecting a helpful walking aid for persons with PD.
Introduction
Gait difficulty is one of the most troubling problems in individuals with Parkinson's disease (PD) [1] . Persons with PD are particularly at risk for falls because of the impact of the disease on postural instability. An improved walking aid could ease gait problems and reduce the risk of falls in persons with PD. The most common device to assist walking in elders is the standard walker. The walker is a mobility aid that provides a portable, enlarged base of support. Interestingly, a standard walker does little to prevent falls as most falls occur in directions that are not protected by a standard walker (e.g. sideways, backward). Furthermore, in 16% of falls, walkers or crutches contribute to the falls [2] .
In one study, patients with PD walked more slowly when using either a standard or wheeled walker compared to walking without a walker but walking speed was less impaired with a wheeled walker [3] . Furthermore, patients were more stable and had more confidence with a wheeled model and wheeled walkers did not aggravate freezing (i.e. transient episodes in which initiation or continuation of walking is halted). The authors concluded that a wheeled walker should be favored for patients with PD.
A walking aid called the WalkAbout is one kind of four-wheeled walker designed to enhance stability, and to ease ambulation. It was designed to enable an unhampered gait while providing protection against falling in any direction. The performance of the WalkAbout has been evaluated in both laboratory and nursing home settings in severely disabled elders who were at high risk of falling and could not walk independently. Results demonstrated that the WalkAbout helped frail elders to walk farther and prevented falls [4] . The WalkAbout has not been tested in the PD population regarding modification of gait patterns.
One of the important tasks in rehabilitation is the selection of a suitable walking device to improve the ambulation of clients. Therapists play a critical role in determining which assistive devices are provided to clients during rehabilitation. This requires a series of decisions and skilled clinical judgments. Although numerous walking devices are used clinically in persons with PD, guidelines for selecting devices have not been objectively identified. Without guidelines, the prescribed walking device may not be optimally beneficial to patients, and/or may limit the utility of the device.
We tested the WalkAbout regarding its effect on gait patterns, energy costs, and its ease of use in individuals with PD. The primary goal of this study was to analyze gait parameters and energy costs in individuals with PD while using the WalkAbout compared to their usual walk. The secondary goal was to compare subject characteristics and gait patterns of persons with PD who showed benefit from using the WalkAbout (responders) to those of subjects who did not show benefit while using the device (non-responders). This information will be helpful for clinicians in considering whether the WalkAbout is a proper walking aid for a particular patient.
Methods

Subjects
Fifteen individuals with PD were recruited from the Innovative Health Solutions; Michael E. DeBakey Veterans Affairs Medical Center and the Houston area. All subjects provided written informed consent before participation. They were tested after taking their regular anti-parkinsonian medications. Their mean age was 75.27 + 7.17 years, with a mean PD duration of 8.23 + 6.14 years. Their mean on the Unified Parkinson Disease Rating Scale (UPDRS) motor score was 23.87 + 5.34 [5] . Their mean Hoehn and Yahr (H&Y) stage was 2.93 + 0.68 (range 2-4) [6] . The average height, weight, and body mass index (BMI) of the subjects were 175.32 + 8.64 cm, 84.00 + 18.16 kg, 27.34 + 5.47 kg/m 2 , respectively. Five subjects usually walked independently without any assistive device. The other 10 subjects usually ambulated with a cane, a wheeled walker, or a wheelchair.
Instruments
The Unified Parkinson Disease Rating Scale (UP-DRS). The UPDRS is a rating scale designed to assess the degree of a person's impairment. It is a standardized scale for patients with PD and is widely used in therapeutic trials and clinical research in persons with PD. The UPDRS consists of both interview and observational tests and has subscales on mentation, activities of daily living, motor examination, and therapeutic complications, with higher scores indicating greater impairment [5] .
The motor examination enables clinicians to quantify the type and severity of the signs and symptoms of the disease (e.g. rigidity, tremor, gait, leg agility, ability to rise from a chair, and postural stability). The complication of therapy section consists of questions regarding motor fluctuations and some other complications that may occur due to interventions.
The Hoehn and Yahr Staging Scale (H&Y). The H&Y scale is used to assess the stage of PD based on the severity of the disease [6] . The scale simply stages the progression or severity of the disease on a 1-5 scale based on whether the symptoms are unilateral or bilateral, there is impairment of balance, or functional capability in relation to normal activities. This scale is frequently used in the clinic and in research as a means of classifying patients according to the severity of their disease. A particular H&Y stage provides a description of where an individual is in the possible progression of the disease.
The WalkAbout. The WalkAbout (Innovative Health Solutions, Inc.) is a wide-based walking device made out of 14-gauge carbon steel that completely encircles the user (Figure 1 ). The WalkAbout has four caster wheels, enabling it to roll easily on the ground. The top rail is approximately waist high to provide stability and confidence. The footprint of the base of the device is larger in circumference than the top rail, so that the four legs are attached to the top rail at an outward angle towards the base to provide maximum stability. There are brakes on the two front wheels for stability while entering, exiting, and sitting on the WalkAbout. The device is easily opened, enabling the user to enter and then close the device unaided. It is fitted with a safety seat called the WalkAbelt, which prevents the user from falling ( Figure 1 ). The WalkAbout moves as the user walks as a result of the attachment of the WalkAbelt to the device. Consequently, the user does not need upper body strength or coordination to walk with the device and is able to rest the arms on the top rail armrest that is padded for comfort. The WalkAbout is designed to support full body weight and able to take a maximum user weight of 300 pounds (135 kg) and a maximum height of 76 inches (193.04 cm). It has a base length (front to back) of 35 00 (88.9 cm) and a base width of 31
00
(78.74 cm). The device has been tested by the manufacturer for various performance parameters in laboratory settings [4] . The structural analysis indicated that the WalkAbout had more than adequate resistance to leg buckling, bending, and splaying with a test weight of 675 kg. Functional testing indicated resistance to tipping to the front, sides, and rear. Simulation analysis of a person collapsing while using the WalkAbout also found the device to be tip resistant.
The WalkAbelt is made of a strong, comfortable material and does not interfere with the user's natural gait. It is adjustable and easy to use and attaches to the top rail with safety hooks. The secure feel of the seat and the solid structure of the WalkAbout support the user and minimize the user's fear of falling. The WalkAbout is designed for use in the natural standing position to enable independent ambulation, and gait rehabilitation. It is not intended to be used for ambulation in the seated position; however it accommodates the user when he/she sits down (Figures 1 and 2 ).
GAITRite. The GAITRite system (GAITRite, CIR Systems, Havertown, PA), is a 3-m, instrumented walkway containing an array of 6 sensor pads encapsulated in a roll-up carpet with an active area 61 cm wide by 366 cm long. As the subject walks, the system continuously scans the sensors to detect pressures, and transfers the information to the connected computer for calculating gait characteristics [7] . Measurement of gait speed, cadence, symmetry, stride length, and other characteristics are recorded and stored in the computer by the system. Gait speed is reported as cm/s. Cadence is the number of steps/min. The stride length is the length (in cm) of two consecutive footfalls of the same extremity.
Step length is measured (in cm) along the horizontal axis, from the heel center of the current footfall to the heel center of the previous footfall on the opposite foot. The reliability of gait speed, cadence, and step length measured from the GAITRite in both young and elderly subjects has been excellent with intraclass correlation coefficients (ICCs) between 0.82 and 0.92 [8] . The portable metabolic analyzer. The portable metabolic analyzer (VO2000 MedGraphics 1 , Medical Graphics Co., St. Paul, MN) is a metabolic measurement system with a transducer-type device designed for operation in conjunction with a computer. The unit consists of a soft face mask, the VO2000, a battery pack with two lithium batteries, and a telemetry-based unit. The entire portable unit is worn in a small pack on the subject's back. The transducer within the VO2000 unit is completely self-contained with an integrated sample pump, micro-proportioning sample valve, and sensors to measure oxygen, carbon dioxide, expired volume, barometric pressure, and ambient temperature. The unit extracts and measures micro samples of expired air from a subject and generates metabolic data via wireless telemetric transmission (Figure 2) . The system requires no calibration syringe or gases, which makes it easy to apply, light weight (740 g), and works up to a distance of 1 km (0.62 mile) by receiving signals through the telemetry-based unit connected to a computer to display 'real time' data [9] . The VO2000 metabolic analysis system determines changes in metabolic functions and measures the volume of oxygen used while performing physical activities. The portable VO 2000 has been found to be valid for measurement of VO 2 [10, 11] . The oxygen uptake measure using VO2000 while performing the 5-min walk was found to be a reliable measure in healthy individuals (ICC ¼ 0.79) (unpublished data).
Procedures
All subjects were scheduled for data collection at least 1 h after they took their usual dose of antiparkinsonian medication. This was to standardize the impact of antiparkinsonian medications on mobility function.
After providing written informed consent, they were asked about their age, years since diagnosis of PD, and the use of assistive devices for walking. They were rated on the motor section of the UPDRS and the H&Y disability scale when they were on antiparkinsonian medications. This was done by a neurologist who has expertise in PD. One of the investigators is a physical therapist and performed all data collection with the GaitRite and the VO2000. All procedures were done in a rehabilitation research laboratory located inside a hospital by the same personnel for every subject to ensure the consistency of data collection.
Gait characteristics. Gait speed, cadence, and stride length were recorded using the GAITRite system. Subjects were asked to independently walk on the GAITRite (with an assistive device if the subject usually used one) at two speeds: self-selected (usual) speed and as fast as possible. A physical therapist guarded the subjects during walking to prevent falls. Subjects completed two trials for each speed on the walkway and the average of the two trials was used as definitive data. Then subjects were placed in the WalkAbout and walked on the walkway twice at their usual speed and twice at their fastest speed.
Gait endurance and oxygen consumption. Gait endurance and oxygen consumption were measured during a 5-min walk test. Subjects were attached to the portable VO 2000 system with a mask over their nose and mouth to measure oxygen uptake while performing the 5-min walk. The subjects walked at their usual speed (with an assistive device if the subject usually used one) and then walked with the WalkAbout in hospital corridors with a smooth, tiled surface.
Questionnaire. After completing the walking tests, subjects responded to a short questionnaire regarding the use of the WalkAbout. The questionnaire asked about perceptions of ease of use, safety, comfort, and likely-hood of future use of the device if it were available.
Statistical analysis
Means and standard deviations of demographic data were descriptively summarized. Paired t-tests were used to compare gait characteristics, gait endurance, and oxygen consumption while walking with and without the WalkAbout. Subjects were classified into two groups -responders and non-responders -based on whether the distance walked during the 5-min walk test improved or not when using the WalkAbout. Independent sample t-tests were used to compare measures between the responders and non-responders. Fisher's Exact test and Pearson Chi-Square were used to compare devise use and responses from the questionnaire. Significance was set at p 0.05. All statistical analyses were performed with SPSS version 13.0 software.
Results
Data were collected from 15 individuals with PD (13 males, 2 females). Their mean age was 75.27 + 7.17 years. The mean of the UPDRS motor score was 23.87 + 5.34. The average H&Y stage was 2.93 + 0.68. This score indicated that they had bilateral disease with balance impairment. The time since PD diagnosis was 8.23 + 6.14 years. The average height, weight, and BMI of the subjects were 175.32 + 8.64 cm, 84.00 + 18.16 kg, 27.34 + 5.47 kg/m 2 , respectively. Five subjects usually walked independently without any walking device. The other 10 subjects usually walked with a walking aid (e.g. a cane (n ¼ 4), a wheeled walker (n ¼ 4), or a wheelchair (n ¼ 2)). Comparisons of their gait characteristics while walking with and without the WalkAbout are shown in Table I . No significant difference in gait characteristics was found during self-selected gait speed. At the fastest gait speed, stride lengths were significantly shorter when using the WalkAbout than those of the usual walk. There was no other significant difference in gait characteristics during the fastest gait speed. Finally, there was no significant difference in oxygen uptake during the 5-min walk with and without the WalkAbout.
There were eight persons (53%) with PD who walked farther during the 5-min walk test with the WalkAbout (responders) compared to their usual walk. There were seven persons (47%) who walked farther without the WalkAbout (non-responders). Table II are comparisons of the characteristics of the responders and non-responders. There were significant differences between the responders and non-responders in age, H&Y stage, usual gait speed, distance walked in 5 min, and the use of a walking aid. Responders were older, had more severe disability, walked more slowly, and walked shorter distances over 5-min than nonresponders. More responders used a walking device than the non-responders. Table III shows responses from the subjects regarding the use of the WalkAbout. In general, responders had a more positive attitude toward using the WalkAbout than non-responders. All responders reported that they felt very safe while walking with the WalkAbout. The majority of the responders felt very comfortable while walking with the WalkAbout, whereas only half of the non-responders did. Nearly all of the responders had confidence that they could walk without falling when walking with the device. All responders reported that it was either very easy or somewhat easy to walk in the walkabout, whereas over half of the non-responders reported that it was somewhat hard to use (p ¼ 0.03).
Displayed in
Discussion
We reported results from a clinical test of the WalkAbout in a sample of persons with mild to moderately severe PD. We compared gait characteristics of the subjects while walking in their usual fashion and in the WalkAbout. When the subjects walked at their self-selected speed, the WalkAbout did not change the gait characteristics compared with the usual walk (Table I ). An earlier study also reported that the WalkAbout did not change gait patterns in older adults from their usual walk [12] . The WalkAbout shortened stride length when the subjects with PD walked at their fastest speed. This modification might be due to the relatively heavy weight of the carbon steel frame that the subjects had to roll while walking. We used the distance walked during the 5-min walk test to classify subjects into two groupsresponders and non-responders. On the basis of the 5-min walk, 8 out of 15 subjects (responders; 53.33%) walked farther when using the WalkAbout compared with their usual walk. Seven subjects (nonresponders; 46.67%) walked a shorter distance while using the WalkAbout compared with their usual walk. The responders were significantly older and had greater severity of PD compared to the nonresponders. Levy et al. [13] demonstrated that the combined effect of the disease and the aging process may cause gait and postural impairment in PD. Older persons and those with more severe PD have more difficulty in ambulation than those who are younger or have less severe PD, thus, our older, more impaired subjects gained more benefit from using the WalkAbout. Another study reported that individuals with PD who fall are also older and exhibit more severe disease than those with PD who do not fall [14] . The responders in our study normally walked slower and had poorer gait endurance than the non-responders but the WalkAbout appeared to improve these parameters in the responders. For the entire sample, compared to the usual walk, the WalkAbout reduced the oxygen demands of walking approximately 13%; however, the change was not statistically significant.
The results found in this study were similar to the WalkAbout testing results in frail elders. Wolfe et al. field-tested the WalkAbout in 65 elderly patients with numerous diagnoses who were deconditioned from inactivity. They reported that 63 out of 65 elders (97%) who usually walked with another assistive device walked farther in the WalkAbout than they did using their usual walking aid [4] . Our results showed that 53% of the subjects with PD walked farther with the WalkAbout. The responders might benefit from the WalkAbout by either using it as a means to reduce the amount of weight transmitted through the lower extremity, or to enhance their balance and stability [15] .
Responses from the questionnaire regarding the use of the WalkAbout demonstrated that most subjects felt safe while walking with the device. This response was in accordance with the report by Wolfe et al. [4] , in which 95% of the subjects reported that they felt safe while walking in the WalkAbout. Most responders felt confident that they could walk without fear of falling when using the device. In another study, fear of falling was reported by 45.8% of the patients with PD, and 44.1% of the patients reported reduced daily activities as a result of falling [16] . A device that can reduce the fear of falling can impact function in this population. However, over half of the subjects in the current study reported that the device was not suitable for use in their living settings. The base of the WalkAbout is 31 inches wide, which is just sufficient to pass through the common apartment doorway of 32 inches. Most residential settings including apartments, condominiums, and houses are not designed for wide-based walking devices. Residential hallways are narrower than the ones in hospital and rehabilitation settings. This might explain why so many of the subjects felt that it was very unlikely they would use the device at home, even though they reported they felt confident about walking without fear of falling. However, the results showed that the device helped patients with moderately severe PD to walk farther, which might be helpful in geriatric institutions and rehabilitation settings. The benefits of walking in terms of maintenance of mobility are virtually self-evident, and the physical health benefits of maintaining mobility are well documented [17] . One limitation of our study is that our subjects were out-patients who came for neurology clinic appointments, and may not have had severe difficulty in walking. As the results suggested, the WalkAbout was more helpful in patients with moderate to severe PD. The WalkAbout needs to be tested with persons with severe PD who receive ambulation training in rehabilitation settings. The device will also need further testing in home environments regarding controlling the device while performing activities of daily living such as opening and closing household appliances (e.g. oven, dryer) and doors, as well as testing its performance when used on ramps and uneven surfaces (e.g. many sidewalks and roadways). These conditions need to be evaluated to ascertain whether the device can be functionally used in various settings. Since we tested only during a single session, we were not able to assess the ability of the device to prevent falls in people with PD. The sequence of the test might have influenced walking performance. We did not randomize the sequence. All subjects were asked to walk without the WalkAbout first, then with the device. Future studies are needed to address these issues.
Conclusion
The results showed that persons with PD who were older, had slower gait speeds, had poorer gait endurance, and had more severe disease benefited more from using the WalkAbout than those who were younger, had faster gait speeds, had better gait endurance, and had less severe disease. The results could be helpful for clinicians in selecting a walking aid for persons with PD by considering age, severity, gait speed, and gait endurance. The WalkAbout could be one means for mobile patients with PD to ambulate farther.
